Paul M Ehrlich
Medical Practice in New York, NY
License number
New Jersey 25MA04174000
Issued Date
Jan 1, 1983
Expiration Date
Jun 30, 1991
Category
Medical Examiners
Type
Medical Doctor
Address
Address
New York, NY
Personal information
See more information about Paul M Ehrlich at radaris.comName
Address
Phone
32 Lincrest St, Syosset, NY 11791
50 Rock Mill Rd #4413, Carmel, NY 10512
606 Metropolitan Ave APT 5A, Brooklyn, NY 11211
670 W End Ave APT 15C, New York, NY 10025
154 Scott Dr, Atlantic Bch, NY 11509
Organization information
See more information about Paul M Ehrlich at bizstanding.comPAUL M EHRLICH CONSULTANTS, LLC
670 W End Ave APARTMENT 15C, New York, NY 10025
Registration:
Feb 11, 2014
State ID:
4527470
Business type:
DOMESTIC LIMITED LIABILITY COMPANY
Professional information
See more information about Paul M Ehrlich at trustoria.com
Paul Ehrlich, New York NY
Paul Ehrlich, New York NY
Specialties:
Allergist, Pediatric Allergist
Address:
35 East 35Th Street, New York, NY 10016
Education:
Medical School - New York University
New York University Elaine A. and Kenneth G. Langone Medical Center (Residency)
New York University Elaine A. and Kenneth G. Langone Medical Center (Residency)
Languages:
English, French, Spanish
Professional Memberships:
American Academy of Pediatrics, American Academy of Allergy, Asthma and Immunology
Board certifications:
American Board of Allergy and Immunology, American Board of Pediatrics
Hospital affiliations:
The New York Eye and Ear Infirmary
About:
Paul M. Ehrlich, MD is a board certified allergist practicing in New York City. He is a graduate of Columbia University where he earned his AB degree and New
York University Schoo...
Senior Director, Team Leader Immuno-Oncology At Pfizer Oncology
Senior Director, Team Leader Immuno-Oncology At Pfizer Oncology
Position:
Senior Director, Team Leader Cell Adhesion/ Anti-angiogenesis/ Immunotherapy at Pfizer Oncology
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Pfizer Oncology
since Jul 2009
-
Senior Director, Team Leader Cell Adhesion/ Anti-angiogenesis/ Immunotherapy
Pfizer Oncology
Mar 2008 - Jun 2009
-
Director, Project Management
Pfizer Ophthalmology
Oct 2007 - Mar 2008
-
Director, Project Management
Bayer HealthCare
Dec 1997 - Sep 2007
-
Director, Global Project Leader, Oncology TA
Abbott Laboratories
Dec 1988 - Nov 1997
-
PPD Research Investigator, Neuroscience
Education:
Colorado State University 1983 - 1988
PhD, Medicinal Chemistry Rochester Institute of Technology 1979 - 1983
BS, Chemistry
PhD, Medicinal Chemistry Rochester Institute of Technology 1979 - 1983
BS, Chemistry
Physician At Self-Employed
Physician At Self-Employed
Position:
Physician at self-employed
Location:
Greater New York City Area
Industry:
Medical Practice
Work:
self-employed
since 1970
-
Physician
New York University
1977 - 2012
-
Physician
US Navy
1973 - 1977
-
Physician
Education:
New York University School of Medicine 1966 - 1970
MD, Pediatric Allergy and Immunology Columbia University in the City of New York 1962 - 1966
AB, Art History
MD, Pediatric Allergy and Immunology Columbia University in the City of New York 1962 - 1966
AB, Art History
Languages:
French, Spanish
Paul Ehrlich
Paul Ehrlich
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Rutgers University
Jun 2002 - Mar 2009
-
Associate Director
Sandoz Pharnmaceuticals Corporation
- E. Hanover, NJ Aug 1984 - Dec 1996
-
Senior Associate Fellow
Education:
Harvard Medical School, Boston, MA 1977 - 1979
M.I.T., Cambridge, MA 1971 - 1977
S.U.N.Y. at Stony Brook, Stony Brook, NY 1967 - 1971
M.I.T., Cambridge, MA 1971 - 1977
S.U.N.Y. at Stony Brook, Stony Brook, NY 1967 - 1971
Engineering Support Manager At Bloomberg News
Engineering Support Manager At Bloomberg News
Position:
Engineering Support Manager at Bloomberg News, engineering at Bloomberg L.P.
Location:
Greater New York City Area
Industry:
Information Technology and Services
Work:
Bloomberg News
-
Engineering Support Manager
Bloomberg L.P.
since 1996
-
engineering
Education:
City University of New York 1986 - 1990
Ceo At Ehrlich Enterprise
Ceo At Ehrlich Enterprise
Position:
CEO at Ehrlich Enterprise
Location:
Greater New York City Area
Industry:
Broadcast Media
Work:
Ehrlich Enterprise
-
CEO
Financial News Network, Bloomberg Radio and TV news
Mar 1983 - May 2003
-
reporter, anchor, management
ABC News Radio
1961 - 1981
-
News Director WABC etc.
Education:
Weequahic High School 1946 - 1950
Harvard College, Johns Hopkins SAIS
BA
Harvard College, Johns Hopkins SAIS
BA
Paul Ehrlich
Paul Ehrlich
Location:
Greater New York City Area
Industry:
Law Practice
Skills:
Litigation
Immunoassay For Human Chorionic Gonadotropin
Immunoassay For Human Chorionic Gonadotropin
US Patent:
4851356, Jul 25, 1989
Filed:
Jul 14, 1987
Appl. No.:
7/072802
Inventors:
Robert E. Canfield - New York NY
Elmo G. Armstrong - Bronx NY
Paul H. Ehrlich - New York NY
Steven Birken - Dumont NJ
Elmo G. Armstrong - Bronx NY
Paul H. Ehrlich - New York NY
Steven Birken - Dumont NJ
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
G01N 3376, G01N 33535, G01N 33543
US Classification:
436510
Abstract:
An immunoassay for detecting and measuring hCG in a sample includes an antibody directed to the carboxy terminal portion of the. beta. subunit of hCG and a monoclonal antibody directed to a determinant on hCG at a locus sufficiently remote from the carboxy terminal portion of the. beta. subunit of hCG that both antibodies can simultaneously bind to hCG, wherein at least one of the antibodies is delectable when both are bound to hCG.
In a presently preferred embodiment, an immunoassay for hCG or hCB. beta. in urine includes a purified, labeled or detectable serum-derived antibody directed to the carboxy-terminal portion of the. beta. subunit of hCG and a matrix-bound monoclonal antibody directed to a locus on the. beta. subunit sufficiently remote from the carboxy-terminal portion that both antibodies can simultaneously bind to hCG or hCG. beta.
Monoclonal Antibody Mixtures And Use Thereof For Enhanced Sensitivity Immunoassays
Monoclonal Antibody Mixtures And Use Thereof For Enhanced Sensitivity Immunoassays
US Patent:
4514505, Apr 30, 1985
Filed:
May 21, 1982
Appl. No.:
6/380959
Inventors:
Robert E. Canfield - New York NY
Paul H. Ehrlich - New York NY
William R. Moyle - Piscataway NJ
Paul H. Ehrlich - New York NY
William R. Moyle - Piscataway NJ
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
G01N 3354, G01N 3374, G01N 3376
US Classification:
436500
Abstract:
Mixtures of monoclonal antibodies which contain effective assaying amounts of each of at least two monoclonal antibodies that bind to different antigenic sites on the antigen and are capable under appropriate conditions of binding simultaneously to an antigen are useful in enhanced sensitivity assays for the antigen. By utilizing such mixtures in diagnostic assays for important antigens such as the polypeptide human chorionic gonadotropin enhanced sensitivity can be achieved as compared with assays employing individual monoclonal antibodies.
Methods For Obtaining Monoclonal Antibodies Useful In Enhanced Sensitivity Immunoassays
Methods For Obtaining Monoclonal Antibodies Useful In Enhanced Sensitivity Immunoassays
US Patent:
4792528, Dec 20, 1988
Filed:
Feb 19, 1987
Appl. No.:
7/016213
Inventors:
Robert E. Canfield - New York NY
Paul H. Ehrlich - New York NY
William R. Moyle - Piscataway NJ
Paul H. Ehrlich - New York NY
William R. Moyle - Piscataway NJ
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
G01N 33537, G01N 33561, G01N 33577
US Classification:
436515
Abstract:
Mixtures of monoclonal antibodies which contain effective assaying amounts of each of at least two monoclonal antibodies that bind to different antigenic sites on the antigen and are capable under appropriate conditions of binding simultaneously to an antigen are useful in enhanced sensitivity assays for the antigen. By utilizing such mixtures in diagnostic assays for important antigens such as the polypeptide human chorionic gonadotropin enhanced sensitivity can be achieved as compared with assays employing individual monoclonal antibodies.